Skip to content
ChickenStockChickenStock
Research237690
ST Pharm logo

ST Pharm (237690) stock

KOSDAQ · Pharmaceuticals

KRW 71,7000.00%(0)

As of Nov 16, 9:44 AM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

19.55x

P/B

2.39x

P/S

3.88x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 108.5 billionKRW 18.3 billionKRW 13.2 billion+58.9%
Q1 2026Consolidated · Filed May 15, 2026KRW 67 billionKRW 11.5 billionKRW 15.2 billion+27.7%
Q4 2025Consolidated · Filed Jun 2, 2026KRW 129.1 billionKRW 26.3 billionKRW 31 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 81.9 billionKRW 14.7 billionKRW 17.5 billion+32.7%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 68.3 billionKRW 12.9 billionKRW 5.4 billion+53.1%
Q1 2025Consolidated · Filed May 15, 2025KRW 52.4 billionKRW 1 billionKRW 700 million+1.4%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Jun 2, 2026KRW 331.7 billionKRW 54.9 billionKRW 54.6 billion+21.2%
FY2024Consolidated · Filed Aug 14, 2025KRW 273.8 billionKRW 27.7 billionKRW 32.5 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
5.80%
Of trading value on Nov 13, 2026
Short-sale value
KRW 630 million
Previous 20-day average 4.91%
Net short position
0 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
913,361 shares
As of Nov 13, 2026 · 4.38% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20265.80%KRW 630 million
Nov 12, 202616.30%KRW 1.24 billion
Nov 11, 20266.24%KRW 570 million
Nov 10, 20263.97%KRW 460 million
Nov 9, 20263.88%KRW 300 million
Nov 6, 20261.50%KRW 190 million
Nov 5, 20262.18%KRW 360 million
Nov 4, 20263.31%KRW 410 million
Nov 3, 20264.46%KRW 500 million
Nov 2, 20264.73%KRW 380 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

ST Pharm (237690) stock information

KOSDAQ

ST Pharm (237690) is listed on KOSDAQ. Its market capitalization is about KRW 1.5 trillion. On trailing-twelve-month earnings the P/E ratio is 19.55, and the P/B ratio is 2.39. Return on equity is 12.2%. These figures are computed in-house from official filings and are reference information only.

ST Pharm — frequently asked questions

What is the P/E ratio of ST Pharm (237690)?
On a trailing-twelve-month basis, 237690 trades at a P/E ratio of 19.55. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of ST Pharm?
237690 has a market capitalization of about KRW 1.5 trillion. The figure moves with the share price and is refreshed each trading day.
Does ST Pharm pay a dividend?
237690 has a dividend yield of about 0.7%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.